Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1913 1
1946 1
1950 1
1962 1
1964 2
1969 1
1998 2
1999 1
2000 1
2003 2
2004 1
2005 2
2007 3
2008 3
2009 2
2010 5
2011 6
2012 9
2013 9
2014 6
2015 10
2016 9
2017 5
2018 7
2019 9
2020 12
2021 12
2022 13
2023 13
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Results by year

Filters applied: . Clear all
Page 1
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases: Updated Exploratory Analysis of the HER2CLIMB Randomized Clinical Trial.
Lin NU, Murthy RK, Abramson V, Anders C, Bachelot T, Bedard PL, Borges V, Cameron D, Carey LA, Chien AJ, Curigliano G, DiGiovanna MP, Gelmon K, Hortobagyi G, Hurvitz SA, Krop I, Loi S, Loibl S, Mueller V, Oliveira M, Paplomata E, Pegram M, Slamon D, Zelnak A, Ramos J, Feng W, Winer E. Lin NU, et al. Among authors: mueller v. JAMA Oncol. 2023 Feb 1;9(2):197-205. doi: 10.1001/jamaoncol.2022.5610. JAMA Oncol. 2023. PMID: 36454580 Free PMC article. Clinical Trial.
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis.
Curigliano G, Mueller V, Borges V, Hamilton E, Hurvitz S, Loi S, Murthy R, Okines A, Paplomata E, Cameron D, Carey LA, Gelmon K, Hortobagyi GN, Krop I, Loibl S, Pegram M, Slamon D, Ramos J, Feng W, Winer E. Curigliano G, et al. Among authors: mueller v. Ann Oncol. 2022 Mar;33(3):321-329. doi: 10.1016/j.annonc.2021.12.005. Epub 2021 Dec 23. Ann Oncol. 2022. PMID: 34954044 Free article. Clinical Trial.
A near-infrared fluorophore for live-cell super-resolution microscopy of cellular proteins.
Lukinavičius G, Umezawa K, Olivier N, Honigmann A, Yang G, Plass T, Mueller V, Reymond L, Corrêa IR Jr, Luo ZG, Schultz C, Lemke EA, Heppenstall P, Eggeling C, Manley S, Johnsson K. Lukinavičius G, et al. Among authors: mueller v. Nat Chem. 2013 Feb;5(2):132-9. doi: 10.1038/nchem.1546. Epub 2013 Jan 6. Nat Chem. 2013. PMID: 23344448 Free article.
Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial.
Lin NU, Borges V, Anders C, Murthy RK, Paplomata E, Hamilton E, Hurvitz S, Loi S, Okines A, Abramson V, Bedard PL, Oliveira M, Mueller V, Zelnak A, DiGiovanna MP, Bachelot T, Chien AJ, O'Regan R, Wardley A, Conlin A, Cameron D, Carey L, Curigliano G, Gelmon K, Loibl S, Mayor J, McGoldrick S, An X, Winer EP. Lin NU, et al. Among authors: mueller v. J Clin Oncol. 2020 Aug 10;38(23):2610-2619. doi: 10.1200/JCO.20.00775. Epub 2020 May 29. J Clin Oncol. 2020. PMID: 32468955 Free PMC article. Clinical Trial.
6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7).
Cardoso F, Paluch-Shimon S, Schumacher-Wulf E, Matos L, Gelmon K, Aapro MS, Bajpai J, Barrios CH, Bergh J, Bergsten-Nordström E, Biganzoli L, Cardoso MJ, Carey LA, Chavez-MacGregor M, Chidebe R, Cortés J, Curigliano G, Dent RA, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Franco Millan SX, Gilchrist J, Gligorov J, Gradishar WJ, Haidinger R, Harbeck N, Hu X, Kaur R, Kiely B, Kim SB, Koppikar S, Kuper-Hommel MJJ, Lecouvet FE, Mason G, Mertz SA, Mueller V, Myerson C, Neciosup S, Offersen BV, Ohno S, Pagani O, Partridge AH, Penault-Llorca F, Prat A, Rugo HS, Senkus E, Sledge GW, Swain SM, Thomssen C, Vorobiof DA, Vuylsteke P, Wiseman T, Xu B, Costa A, Norton L, Winer EP. Cardoso F, et al. Among authors: mueller v. Breast. 2024 Aug;76:103756. doi: 10.1016/j.breast.2024.103756. Epub 2024 May 28. Breast. 2024. PMID: 38896983 Free PMC article.
Systemic treatment of vulvar cancer.
Mahner S, Prieske K, Grimm D, Trillsch F, Prieske S, von Amsberg G, Petersen C, Mueller V, Jaenicke F, Woelber L. Mahner S, et al. Among authors: mueller v. Expert Rev Anticancer Ther. 2015 Jun;15(6):629-37. doi: 10.1586/14737140.2015.1037837. Epub 2015 May 21. Expert Rev Anticancer Ther. 2015. PMID: 25997120 Review.
Efficacy of Lapatinib in Patients with HER2-Negative Metastatic Breast Cancer and HER2-Positive Circulating Tumor Cells-The DETECT III Clinical Trial.
Fehm T, Mueller V, Banys-Paluchowski M, Fasching PA, Friedl TWP, Hartkopf A, Huober J, Loehberg C, Rack B, Riethdorf S, Schneeweiss A, Wallwiener D, Meier-Stiegen F, Krawczyk N, Jaeger B, Reinhardt F, Hoffmann O, Mueller L, Wimberger P, Ruckhaeberle E, Blohmer JU, Cieslik JP, Franken A, Niederacher D, Neubauer H, Pantel K, Janni W; DETECT Study Group. Fehm T, et al. Among authors: mueller v. Clin Chem. 2024 Jan 4;70(1):307-318. doi: 10.1093/clinchem/hvad144. Clin Chem. 2024. PMID: 38175595 Clinical Trial.
Comparative analysis of EpCAM high-expressing and low-expressing circulating tumour cells with regard to their clonal relationship and clinical value.
Franken A, Kraemer A, Sicking A, Watolla M, Rivandi M, Yang L, Warfsmann J, Polzer BM, Friedl TWP, Meier-Stiegen F, Stoecklein NH, Dayan D, Riethdorf S, Mueller V, Pantel K, Koch A, Hartkopf AD, Krawczyk N, Ruckhaeberle E, Niederacher D, Fehm T, Neubauer H. Franken A, et al. Among authors: mueller v. Br J Cancer. 2023 May;128(9):1742-1752. doi: 10.1038/s41416-023-02179-0. Epub 2023 Feb 23. Br J Cancer. 2023. PMID: 36823365 Free PMC article.
136 results